Status:
COMPLETED
Clinical Outcomes of Levosimendan Versus Dobutamine Versus Milrinone in Cases With Acute Decompensated Heart Failure With Impaired Renal Function
Lead Sponsor:
Ain Shams University
Conditions:
Acute Decompensated Heart Failure (ADHF)
Cardiorenal Syndrome (CRS)
Eligibility:
All Genders
18+ years
Brief Summary
This study aimed to assess and compare the cardiac, renal, and clinical efficacy of Levosimendan (LEV), Dobutamine (DOB), and milrinone (MIL) in cases with acute decompensated heart failure (ADHF) com...
Detailed Description
Methods Upon ICU admission and once the clinical decision to initiate inotropic therapy was made, all enrolled patients underwent a standardized evaluation protocol that included: Comprehensive medica...
Eligibility Criteria
Inclusion
- Adult (\>18 years old) patients with ADHF (LVEF ≤ 40% documented prior to enrollment) admitted to the ICU with renal impairment (estimated GFR between 30 and 60 mL/min/1.73 m², calculated using the Modification of Diet in Renal Disease Study equation (MDRD equation)) and require inotropic support.
Exclusion
- Cases were excluded from the study if they met any of the following criteria:
- Age younger than 18 years
- Untreated acute HF
- Resting heart rate exceeding 120 beats per minute
- Recent MI or acute coronary syndrome within the previous two months
- Diagnosed pulmonary embolism
- Structural cardiac conditions
- Known history of kidney disease diagnosed prior to HF
- Administration of contrast agents or nephrotoxic drugs within the previous seven days
- Severe liver dysfunction (Child C)
- Active acute inflammatory or infectious diseases.
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT07186062
Start Date
June 1 2022
End Date
June 1 2024
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
faculty of medicine Ain shams University
Cairo, Egypt